论文部分内容阅读
水飞蓟素(silymarin)具有保护实验动物免受肝毒性物质侵害的作用。为明确其对肝硬化的疗效,作者对170例肝硬化患者进行前瞻性随机双盲研究。材料和方法:170例肝硬化,70%经病理学证实。病例选择时已剔除肝衰竭、恶性肿瘤、接受免疫抑制剂治疗、原发性胆汁性肝硬化和不能合作的病例。肝损害程度按Child-Turcotte标准分级,病因根据临床、生化、免疫和组织学标准确定。随机把患者分为治疗组和对照组,分别给予水飞蓟素140 mg每日三次口服,或给予外形相同的安慰剂。平均治疗时间41个月(2～6年)。研究期间患者须戒酒,并不得使用皮质类固醇和
Silymarin has the effect of protecting experimental animals from hepatotoxic substances. To clarify its effect on cirrhosis, the authors conducted a prospective, randomized, double-blind study of 170 cirrhotic patients. Materials and Methods: 170 cases of cirrhosis, 70% confirmed by pathology. Case selection has been removed liver failure, cancer, immunosuppressive agents, primary biliary cirrhosis and can not cooperate with the case. The degree of liver damage was graded according to Child-Turcotte criteria and the cause was determined on the basis of clinical, biochemical, immunological and histological criteria. Patients were randomly divided into treatment group and control group, were given silymarin 140 mg orally three times daily, or given the same shape placebo. The average treatment time of 41 months (2 to 6 years). Patients should be abstinent from alcohol during the study period, and corticosteroids should not be used